Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma

Bibliography

• Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Sleijfer S, Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii89-93
   PubMedGoogle Scholar
• Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17:150-7
   PubMed Web of Science ®Google Scholar
• Italiano A, Mathoulin-Pelissier S, Cesne AL, Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117:1049-54
   PubMed Web of Science ®Google Scholar
• Cheng EY. Surgical management of sarcomas. Hematol Oncol Clin North Am 2005;19:451-70; v
   PubMed Web of Science ®Google Scholar
• Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002;7:348-59
   PubMed Web of Science ®Google Scholar
• O'Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999;56:13-23
   PubMed Web of Science ®Google Scholar
• Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;CD003293
   Google Scholar
• Bramwell VHC, Anderson D, Charette M; and the members of the cancer care ontario practice guidelines initiative sarcoma disease site group. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 2000;4:103-12
   PubMedGoogle Scholar
• Bui-Nguyen B, Ray-Coquard I, Chevreau C, on behalf of the GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Verweij J, Mouridsen HT, Nielssen OS, The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201
   PubMed Web of Science ®Google Scholar
• Rinehart KL. Antitumor compounds from tunicates. Med Res Rev 2000;20(1):1-27
   PubMed Web of Science ®Google Scholar
• Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 2006;7:317-28
   PubMedGoogle Scholar
• D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9:2157-63
   PubMed Web of Science ®Google Scholar
• Martinez N, Sanchez-Beato M, Carnero A, Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005;4:814-23
   PubMed Web of Science ®Google Scholar
• Erba E, Bergamaschi D, Bassano L, Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105
   PubMed Web of Science ®Google Scholar
• Martinez EJ, Corey EJ, Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8:1151-60
   PubMed Web of Science ®Google Scholar
• Damia G, Silvestri S, Carrassa L, Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Zimonjic DB, Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6
   PubMed Web of Science ®Google Scholar
• Soares DG, Escargueil AE, Poindessous V, Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104:13062-7
   PubMed Web of Science ®Google Scholar
• Herrero AB, Martin-Castellanos C, Marco E, Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-62
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010;11:196-207
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Erba E, Damia G, Unique features of the mode of action of ET-743. Oncologist 2002;7:210-16
   PubMed Web of Science ®Google Scholar
• Ryan DP, Supko JG, Eder JP, Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42
   PubMed Web of Science ®Google Scholar
• Beumer JH, Rademaker-Lakhai JM, Rosing H, Trabectedin (Yondelis(TM), formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005;23:429-36
   PubMed Web of Science ®Google Scholar
• van Kesteren C, de Vooght MM, Lopez-Lazaro L, Yondelis trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 2003;14:487-502
   PubMed Web of Science ®Google Scholar
• Reid JM, Kuffel MJ, Ruben SL, Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002;8:2952-62
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-53
   PubMed Web of Science ®Google Scholar
• Brandon EF, Meijerman I, Klijn JS, In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005;16:935-43
   PubMed Web of Science ®Google Scholar
• Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005;6:780-9
   PubMed Web of Science ®Google Scholar
• Izbicka E, Lawrence R, Raymond E, In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-7
   PubMed Web of Science ®Google Scholar
• Hendriks HR, Fiebig HH, Giavazzi R, High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999;10:1233-40
   PubMed Web of Science ®Google Scholar
• Taamma A, Misset JL, Riofrio M, Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-65
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A, Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-51
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-90
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-9
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Yovine A, Blay JY, A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Grosso F, Dileo P, Sanfilippo R, Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42:1484-90
   PubMed Web of Science ®Google Scholar
• Delaloge S, Yovine A, Taamma A, Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001;19(5):1248-55
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Mehren M, Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase 2 study of two different schedules. J Clin Oncol 2009;27(25):4188-96
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Maki RG, Ectenascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23(24):5484-92
   PubMed Web of Science ®Google Scholar
• Grosso F, Jones RL, Demetri GD, Efficacy of trabectedin (ecteinascidin- 732) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
   PubMed Web of Science ®Google Scholar
• Grosso F, Sanfilippo R, Virdis E, Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44
   PubMed Web of Science ®Google Scholar
• Forni C, Minuzzo M, Virdis E, Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8:449-57
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Griffin LB, Yeung C, Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13:145-53
   PubMed Web of Science ®Google Scholar
• Takahashi N, Li WW, Benerjee D, Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET743) with doxorubicine and paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7:3251-7
   PubMed Web of Science ®Google Scholar
• Meco D, Colombo T, Ubezio P, Effective combination of ET743 and doxorubicine in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-8
   PubMed Web of Science ®Google Scholar
• Blay JY, Von Mehren M, Sommels BL, Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin Cancer Res 2008;14:6656-62
   PubMed Web of Science ®Google Scholar
• Cohen RB, Schilder RJ, Cheng J, Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies. J Clin Oncol 2005;23(Suppl):abstract 3074
   Google Scholar
• Schoffski P, Taron M, Jimeno J, Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011;47:1006-12
   PubMed Web of Science ®Google Scholar
• Gossage L, Madhusudan S. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007;11:361-80
   PubMed Web of Science ®Google Scholar
• Robert J, Morvan VL, Smith D, Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54:171-96
   PubMed Web of Science ®Google Scholar
• Italiano A, Laurand A, Laroche A, ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011; [Epub ahead of print]
   Google Scholar
• McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004;31(2 Suppl 6):30-6
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Van Glabbeke M, Rankin CJ, Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two Phase II clinical trials. J Clin Oncol 2010;28:1772-9
   PubMed Web of Science ®Google Scholar
• Fata F, O'Reilly E, Ilson D, Paclitaxel in the treatment of patients with angiosarcom of the scalp or face. Cancer 1999;86:2034-7
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO, Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
   PubMed Web of Science ®Google Scholar
• Patel SR, Gandhi V, Jenkins J, Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-9
   PubMed Web of Science ®Google Scholar
• Pautier P, Bui Nguyen B, Penel N, Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2009;27(15 Suppl):abstract 10527
   Google Scholar
• Italiano A, Delcambre C, Hostein I, Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-7
   PubMed Web of Science ®Google Scholar
• Soini EJ, Garcia San Andres B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol 2011;22:215-23
   PubMed Web of Science ®Google Scholar